Title: Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus
genotype 2: a systematic review and meta-analysis
Version: 1 Date: 09 Mar 2024
Reviewer's report:
I reviewed the manuscript entitled “Efficacy and safety of direct-acting antiviral regimen for
patients with hepatitis C virus genotype 2: A systematic review and meta-analysis”.
This systematic review and meta-analysis aimed to summarize the evidence on efficacy
and safety of DAAs in patients infected with HCV GT2. The authors compared DAA-
based treatments indirectly using meta-analysis and found regimens containing sofosbuvir and
velpatasvir for 12 weeks to be the relatively safe and most effective option for HCV GT2
patients.
Please find my comments:
(1) There are also limitations to this study. The population of GT2 is relatively small, therefore
the authors should be more cautious in their conclusion when they stated that regimens
containing sofosbuvir and velpatasvir for 12 weeks to be the relatively safe and most effective
option for HCV GT2 patients. Their data does not allow to conclude that sofosbuvir and
velpatasvir is better than glecaprevir penbratasvir.
(2) The data from independent clinical trials found that DAA-based treatments are safe and
effective, therefore it was obvious that a meta-analysis will find the same. What is the reason
for this paper ?
Title: Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus
genotype 2: a systematic review and meta-analysis
Version: 1 Date: 09 Mar 2024
Reviewer's report:
I reviewed the manuscript entitled “Efficacy and safety of direct-acting antiviral regimen for
patients with hepatitis C virus genotype 2: A systematic review and meta-analysis”.
This systematic review and meta-analysis aimed to summarize the evidence on efficacy
and safety of DAAs in patients infected with HCV GT2. The authors compared DAA-
based treatments indirectly using meta-analysis and found regimens containing sofosbuvir and
velpatasvir for 12 weeks to be the relatively safe and most effective option for HCV GT2
patients.
Please find my comments:
(1) There are also limitations to this study. The population of GT2 is relatively small, therefore
the authors should be more cautious in their conclusion when they stated that regimens
containing sofosbuvir and velpatasvir for 12 weeks to be the relatively safe and most effective
option for HCV GT2 patients. Their data does not allow to conclude that sofosbuvir and
velpatasvir is better than glecaprevir penbratasvir.
(2) The data from independent clinical trials found that DAA-based treatments are safe and
effective, therefore it was obvious that a meta-analysis will find the same. What is the reason
for this paper ?
Please review this paper.
user
Title: Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus
genotype 2: a systematic review and meta-analysis
Version: 1 Date: 09 Mar 2024
Reviewer's report:
I reviewed the manuscript entitled “Efficacy and safety of direct-acting antiviral regimen for
patients with hepatitis C virus genotype 2: A systematic review and meta-analysis”.
This systematic review and meta-analysis aimed to summarize the evidence on efficacy
and safety of DAAs in patients infected with HCV GT2. The authors compared DAA-
based treatments indirectly using meta-analysis and found regimens containing sofosbuvir and
velpatasvir for 12 weeks to be the relatively safe and most effective option for HCV GT2
patients.
Please find my comments:
(1) There are also limitations to this study. The population of GT2 is relatively small, therefore
the authors should be more cautious in their conclusion when they stated that regimens
containing sofosbuvir and velpatasvir for 12 weeks to be the relatively safe and most effective
option for HCV GT2 patients. Their data does not allow to conclude that sofosbuvir and
velpatasvir is better than glecaprevir penbratasvir.
(2) The data from independent clinical trials found that DAA-based treatments are safe and
effective, therefore it was obvious that a meta-analysis will find the same. What is the reason
for this paper ?
assistant